A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Pegapamodutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OPKO Health
- 09 Nov 2018 According to an OPKO Health media release, topline results from the trial are anticipated during 1Q 2019.
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Status changed from recruiting to active, no longer recruiting, according to an OPKO Health media release.